17 AUG 2018 BIOTECH DAILY
If there’s ever a case of the devil being in the detail, it’s the animal and human health outfit’s fall from investor grace after releasing an investor presentation on May 15 about its newly-inked animal health distribution deal with global giant Zoetis. Anatara shares lost almost 40 percent over the next two trading days, because the disclosed financial terms simply were not as tasty as investors expected. At least the company managed to forge a deal, unlike so many other biotechs.
Anatara’s interim CEO Dr Tracie Ramsdale said the company was pleased with the Zoetis deal because it was expanded to include multiple livestock, rather than just pigs.
To read the full article, please click here: 180820 – Dr Boreham’s Crucible – ANR Aug 17, 2018